登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 28 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 28
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心山东省肿瘤医院Cancer Hospital, Shandong First Medical University济南医院页面
- 研究中心重庆大学附属肿瘤医院Chongqing University Cancer Hospital重庆医院页面
- 研究中心安徽医科大学第一附属医院First Affiliated Hospital of Anhui Medical University合肥医院页面
- 研究中心广州医科大学附属第一医院First Affiliated Hospital of Guangzhou Medical University广州医院页面
- 研究中心南昌大学第一附属医院First Affiliated Hospital of Nanchang University南昌医院页面
- 研究中心苏州大学附属第一医院First Affiliated Hospital of Soochow University苏州医院页面
- 研究中心西安交通大学第一附属医院First Affiliated Hospital of Xi'an Jiaotong University西安医院页面
- 研究中心厦门大学附属第一医院First Affiliated Hospital of Xiamen University厦门医院页面
- 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
- 研究中心中国医科大学附属第一医院First Hospital of China Medical University沈阳医院页面
- 研究中心河北医科大学第四医院Fourth Hospital of Hebei Medical University石家庄医院页面
- 研究中心广西医科大学附属肿瘤医院Guangxi Medical University Cancer Hospital南宁医院页面
- 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
- 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
- 研究中心江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面
- 研究中心临沂市肿瘤医院Linyi Cancer Hospital临沂医院页面
- 研究中心中国医学科学院肿瘤医院National Cancer Center / Cancer Hospital, CAMS北京医院页面
- 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
- 研究中心同济大学附属东方医院Shanghai East Hospital, Tongji University上海医院页面
- 研究中心上海市肺科医院Shanghai Pulmonary Hospital上海医院页面
- 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
- 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
- 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
- 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面
- 研究中心四川大学华西医院West China Hospital成都医院页面
- 研究中心云南省肿瘤医院Yunnan Cancer Hospital昆明医院页面
- 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面
- 研究中心复旦大学附属中山医院Zhongshan Hospital, Fudan University上海医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06564324,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed diagnosis of locally advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC.
入选标准第 1 条
All toxicities from prior anticancer therapy have resolved to ≤ Grade 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0), or have resolved to previous baseline, at the time of randomization.
入选标准第 15 条
Previously received more than 1 regimen of systemic anticancer therapy for locally advanced or metastatic disease.
排除标准第 4 条
Had major surgery within 28 days prior to randomization. Minor surgical procedures, such as catheter placement or minimally invasive biopsy, are allowed.
排除标准第 5 条
Eastern Cooperative Oncology Group (ECOG) performance status zero (0) to 1.
入选标准第 6 条
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT): ≤3.0 × upper limit of normal (ULN) (or ≤5.0 × ULN, for participants with concurrent liver metastases).
入选标准第 9 条
Serum total bilirubin: ≤1.5 × ULN (≤3.0 × ULN for participants with Gilbert syndrome).
入选标准第 10 条
Absolute neutrophil count: ≥1500/μL.
入选标准第 11 条
Platelet count: ≥75,000/μL.
入选标准第 12 条
Hemoglobin: ≥9.0 g/dL.
入选标准第 13 条
Estimated creatinine clearance (CLcr) ≥45 mL/min as calculated using the method standard for the institution (e.g., Cockcroft-Gault Equation, i.e., CCr={((140-age)×weight)/(72×SCr)}×0.85 (if female) (Cockcroft and Gault 1976).
入选标准第 14 条
Have been diagnosed with another primary malignancy other than NSCLC except for adequately treated nonmelanoma skin cancer or cervical cancer in situ; definitively treated nonmetastatic prostate cancer; or participants with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy.
排除标准第 9 条
Be pregnant or breastfeeding
排除标准第 15 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06564324,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Histologically or cytologically confirmed diagnosis of locally advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC. Have documentation of ROS1 rearrangement by a positive result Have at least 1 measurable (i.e., target) lesion by Investigator assessment per RECIST v1.1. Prior brain metastases allowed if asymptomatic and diagnosed incidentally at study baseline. If participants have neurological symptoms or signs due to CNS metastasis, participants need to complete local therapy (surgery and/or radiation) at least 7 days before enrollment and be clinically stable without requiring for an increasing dose of corticosteroids or use of anticonvulsants to control symptoms. Age ≥18 years (or ≥20 years as required by local regulations). Eastern Cooperative Oncology Group (ECOG) performance status zero (0) to 1. Minimum life expectancy of 3 months or more. Adequate organ function meeting the following criteria: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT): ≤3.0 × upper limit of normal (ULN) (or ≤5.0 × ULN, for participants with concurrent liver metastases). Serum total bilirubin: ≤1.5 × ULN (≤3.0 × ULN for participants with Gilbert syndrome). Absolute neutrophil count: ≥1500/μL. Platelet count: ≥75,000/μL. Hemoglobin: ≥9.0 g/dL. Estimated creatinine clearance (CLcr) ≥45 mL/min as calculated using the method standard for the institution (e.g., Cockcroft-Gault Equation, i.e., CCr={((140-age)×weight)/(72×SCr)}×0.85 (if female) (Cockcroft and Gault 1976). All toxicities from prior anticancer therapy have resolved to ≤ Grade 1 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v5.0), or have resolved to previous baseline, at the time of randomization. The participant is willing and capable of giving written informed consent.排除标准:Exclusion Criteria:
Previously received an investigational antineoplastic agent for NSCLC. Previously received any prior TKI, including ROS1-targeted TKIs. Received immune checkpoint inhibitors for locally advanced or metastatic disease. Previously received more than 1 regimen of systemic anticancer therapy for locally advanced or metastatic disease. Had major surgery within 28 days prior to randomization. Minor surgical procedures, such as catheter placement or minimally invasive biopsy, are allowed. Have symptomatic CNS metastases at Screening or asymptomatic disease requiring an increasing dose of corticosteroids to control symptoms within 7 days prior to randomization. Participants with no prior history of signs or symptoms of CNS metastases but who receive prophylactic steroids or anticonvulsants are allowed. Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Participants with leptomeningeal disease and without cord compression are allowed. Uncontrolled pleural, abdominal, or pericardial effusion within 28 days prior to randomization, which is associated with malignant effusion requiring recurrent drainage procedures (once monthly or more frequently). Have been diagnosed with another primary malignancy other than NSCLC except for adequately treated nonmelanoma skin cancer or cervical cancer in situ; definitively treated nonmetastatic prostate cancer; or participants with another primary malignancy who are definitively relapse-free with at least 3 years elapsed since the diagnosis of the other primary malignancy. Have clinically significant cardiovascular diseases within 6 months prior to randomization: myocardial infarction, severe/unstable angina, coronary/peripheral endovascular treatment, heart failure, cerebrovascular disorder including transient ischemic attack, pulmonary embolism, deep venous thrombosis and or other clinically significant thrombosis. Have a known history of uncontrolled hypertension. Participants with hypertension should be under treatment on study entry to control blood pressure. Have ongoing cardiac dysrhythmias of ≥CTCAE Grade 2, uncontrolled atrial fibrillation of any grade, or QT interval corrected for heart rate by Fredericia's formula (QTcF) >470 milliseconds (female) or >450 milliseconds (male), or symptomatic bradycardia <45 bpm within 6 months before enrollment; participants treated with medications known to be associated with the development of TdP . Have active and clinically significant bacterial, fungal, or viral infection including but not limited to hepatitis B virus (HBV), hepatitis C virus (HCV), known HIV or AIDS-related illness Currently have or have a history of interstitial lung disease (ILD), drug-related pneumonitis, or radiation pneumonitis that required steroid treatment. Be pregnant or breastfeeding
引自 ClinicalTrials.gov, NCT06564324, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06564324,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。